Drug news
NICE recommends Harvoni (ledipasvir + sofosbuvir) for treatment of hepatitis C genotypes 1 and 4- Gilead
The National Institute for Health and Care Excellence in draft guidelines recommends Harvoni (ledipasvir + sofosbuvir) for patients with genotype 1 and genotype 4 hepatitis C. Harvoni is a once a day, oral, drug which offers interferon and ribavirin free treatment with a potential short course of eight weeks.
Comment: Harvoni offers advantages of a reduction of the complications found with interferon such as liver cirrhosis and is likely to encourage compliance and a reduction in transmission of the disease.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.